1 / 6

Bipolar Disorder Global Drug Forecast and Market Analysis

Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period.

RahulSharma147
Télécharger la présentation

Bipolar Disorder Global Drug Forecast and Market Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PharmaPoint Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024 Telephone: +1 (800) 910-6452 Mail at: sales@researchbeam.com

  2. Report Overview Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka’s Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period. Key Questions Answered - The bipolar disorder market is heavily genericized and many key players have chosen to deprioritize the indication. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period? - The current late-stage bipolar disorder pipeline is sparse, with only two products in Phase III development. What impact will these drugs have on the market? How will they affect the treatment algorithm for bipolar disorder? Will these drugs fulfil any of the unmet needs for bipolar disorder? - The management of bipolar disorder patients is challenging and a large number of variables can impact treatment outcomes. How does the diagnosis and treatment of bipolar disorder differ amongst the 8MM? Which treatment options are most commonly prescribed in each market, and how will prescribing patterns change over the forecast period?

  3. Table of Contents 1 Table of Contents 1 Table of Contents 12 2 Introduction 26 2.1 Catalyst 26 2.2 Related Reports 27 3 Disease Overview 28 3.1 Etiology and Pathophysiology 28 3.2 Classification 34 3.3 Symptoms 40 4 Epidemiology 43 4.1 Disease Background 43 4.2 Risk Factors and Comorbidities 43 4.3 Global Trends 45 4.4 Forecast Methodology 47 4.5 Epidemiological Forecast of Bipolar Disorder (2014-2024) 60 5 Disease Management 85 5.1 Diagnosis Overview 85 5.2 Treatment Overview 88 5.2.1 Treatment Initiation and Maintenance Therapy 88 5.3 Treatment Guidelines and Leading Prescribed Drugs 105 5.4 US 106 6 Competitive Assessment 125

  4. Table of Contents 7 Unmet Need and Opportunity 270 7.1 Overview 270 7.2 Effective Treatment Options for Bipolar Depression 271 7.3 Antipsychotics with a Low Risk of EPS and Metabolic Changes 276 7.4 Mood Stabilizers with Improved Safety Profiles 279 7.5 Education for Physicians in Order to Improve Diagnosis Rates 284 7.6 Novel Drugs Developed Specifically for Bipolar Disorder 286 8 Pipeline Assessment 290 8.1 Overview 290 9 Current and Future Players 314 9.1 Overview 314 9.2 Trends in Corporate Strategy 317 10 Market Outlook 341 10.1 Global Markets 341 10.2 United States 349 10.2.1 Forecast 349 10.3 5EU 356 11 Appendix 378 11.1 Bibliography 378 11.2 Abbreviations 413 11.3 Methodology 418

  5. Report Ordering Report Name: PharmaPoint Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024 Product Price User Price Single User US $ 9346 Site User US $ 21990 Global user US $ 32985 To View Sample or Purchase Report

  6. Contact Us FOR MORE DETAILS Visit us at : http://www.researchbeam.com/pharmapoint-bipolar-disorder-global-drug-forecast-and-analysis-to- 2024-market/ Stay With Us At: TELEPHONE: +1 (800) 910-6452 DIRECT: +1 (503) 894-6022 E-MAIL: sales@researchbeam.com 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States

More Related